Skip to content

Chapters ENES DE

XExtension Codes
Substances
XM6S30Medicaments
XM3973Agents primarily affecting the cardiovascular system
Cardiac stimulants
XM5JS3Cardiac glycosides

XM6GX1 category

Strophanthus glycosides

2 subordinate codes

XM30Z9Cymarin
XM9YU9g-Strophanthin

Also indexed as

Strophanthus glycosides

Nearby in Cardiac glycosides

XM2EL5Digitalis glycosides
XM71V6Scilla glycosides
XM3WU3Peruvoside

PreviousXM71V6 — Scilla glycosides NextXM3WU3 — Peruvoside

Browse ICD-11

01Certain infectious or parasitic diseases
02Neoplasms
03Diseases of the blood or blood-forming organs
04Diseases of the immune system
05Endocrine, nutritional or metabolic diseases
06Mental, behavioural or neurodevelopmental disorders
07Sleep-wake disorders
08Diseases of the nervous system
09Diseases of the visual system
10Diseases of the ear or mastoid process
11Diseases of the circulatory system
12Diseases of the respiratory system
13Diseases of the digestive system
14Diseases of the skin
15Diseases of the musculoskeletal system or connective tissue
16Diseases of the genitourinary system
17Conditions related to sexual health
18Pregnancy, childbirth or the puerperium
19Certain conditions originating in the perinatal period
20Developmental anomalies
21Symptoms, signs or clinical findings, not elsewhere classified
22Injury, poisoning or certain other consequences of external causes
23External causes of morbidity or mortality
24Factors influencing health status or contact with health services
25Codes for special purposes
26Supplementary Chapter Traditional Medicine Conditions
VSupplementary section for functioning assessment
XExtension Codes
Histopathology
Dimensions of injury
Dimensions of external causes
Consciousness
Substances
Diagnosis code descriptors
Capacity or context
Health Devices, Equipment and Supplies
Extension codes of particular relevance to skin diseases
5 more
XM6S30Medicaments
XM9N55Substances, chiefly nonmedicinal
Allergens
XM3KY1Agents affecting genitourinary system, sex or anabolic hormones
XM26S4Hormones and their synthetic substitutes or antagonists, not elsewhere classified
XM9W63Agents affecting bones, joints or other connective tissue, not elsewhere classified
XM4TG8Agents primarily affecting water and nutrition-balance or metabolism
XM3973Agents primarily affecting the cardiovascular system
XM6CH2Drugs primarily affecting the autonomic nervous system
XM7YD4Drugs used in addictive disorders
XM8014Antivertigo and motion sickness preparations
XM1950Agents primarily acting on smooth and skeletal muscles or the respiratory system
14 more
Agents acting on the renin-angiotensin system
Antihyperlipidemic and antiarteriosclerotic drugs
Calcium-channel blockers
Cardiac stimulants
Antiarrhythmics
Other antihypertensive drugs
Vasodilators used in cardiac diseases
Peripheral vasodilators
Other agents primarily affecting the cardiovascular system
2 more
XM5JS3Cardiac glycosides
XM2PQ4Phosphodiesterase inhibitors
XM1K71Predominantly alpha-adrenoreceptor and dopamine receptor agonists
Predominantly beta-adrenoreceptor agonists
XM7YK1Alpha acetyldigoxin
XM0SY1b-acetyldigoxin
XM91S1Cardiotonic (glycoside)
XM1W74Cerberin
XM5NG4Ch'an su
19 more
XM2EL5Digitalis glycosides
XM71V6Scilla glycosides
XM6GX1Strophanthus glycosides
XM3WU3Peruvoside
XM30Z9Cymarin
XM9YU9g-Strophanthin

International Classification of Diseases, Eleventh Revision (ICD-11), World Health Organization (WHO) 2019/2021, https://icd.who.int/browse11. Licensed under Creative Commons Attribution-NoDerivatives 3.0 IGO (CC BY-ND 3.0 IGO).

Release 2026-01. View this entity in the official WHO ICD-11 browser.

This page reproduces WHO classification content for reference. It is not medical advice and must not be used to diagnose or treat. For coding decisions, consult the official release and your national coding guidelines.

About · Data & methodology · Privacy · Contact